KALA BIO Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

KALA BIO şirketinin toplam hissedar öz sermayesi $13.7M ve toplam borcu $36.8M olup, bu da borç-öz sermaye oranını 268.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $61.6M ve $47.9M dir.

Anahtar bilgiler

268.3%

Borç/özkaynak oranı

US$36.80m

Borç

Faiz karşılama oranı	n/a
Nakit	US$54.20m
Eşitlik	US$13.72m
Toplam yükümlülükler	US$47.89m
Toplam varlıklar	US$61.61m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0JQ2 'nin kısa vadeli varlıkları ( $58.9M ) kısa vadeli yükümlülüklerini ( $19.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0JQ2 şirketinin kısa vadeli varlıkları ( $58.9M ) uzun vadeli yükümlülüklerini ( $28.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0JQ2 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 0JQ2 şirketinin borç/öz sermaye oranı son 5 yılda 164.8% seviyesinden 268.3% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0JQ2 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 0JQ2 serbest nakit akışı her yıl % { 7.8 1.5 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

KALA BIO Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Recent updates

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings released: US$29.48 loss per share (vs US$109 loss in FY 2021)

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.56 loss in 2Q 2021)

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Insufficient new directors

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings released: US$0.45 loss per share (vs US$0.49 loss in 1Q 2021)

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings released: US$2.19 loss per share (vs US$1.99 loss in FY 2020)

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

Insufficient new directors

Insufficient new directors

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

New 90-day low: US$6.86

Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019)

Revenue misses expectations

Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Kala Pharmaceuticals, Inc. Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin